Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

PharmaCyte Biotech Inc. (PMCB)

Add PMCB Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Peacefulwendy, $Pistol Pete$, thenewmixer, fraum, concordia
Search This Board: 
Last Post: 9/22/2017 7:40:37 PM - Followers: 785 - Board type: Free - Posts Today: 33

Welcome to PharmaCyte BioTech
An OTCQB Company

PharmaCyte is a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as "Cell-in-a-Box." This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. For cancer, the therapy involves encapsulating genetically engineered human cells that convert the prodrug ifosfamide from its inactive form to its "cancer" killing form. These encapsulated live cells are implanted in a patient as close to the tumor as possible. Then ifosfamide is given IV at one-third the normal dose. When the ifosfamide comes in contact with the encapsulated live cells, they act as an artificial liver (where ifosfamide is normally activated) and activate the ifosfamide at the source of the cancer. For diabetes, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a "bio-artificial pancreas" for purposes of insulin production.



FDA Grants Orphan Drug Designation to Pharmacyte Biotech for Pancreatic Cancer Treatment

European Medicines Agency (EMA), the European Commission has granted the Orphan Drug designation to PharmaCyte’s subsidiary,
PharmaCyte Biotech Europe Limited, for PharmaCyte’s pancreatic cancer treatment

 Company Address
PharmaCyte Biotech, Inc.

23046 Avenida de la Carlota, Suite 600
Laguna Hills, California 92652
Office Number: 917.595.2850
Facsimile Number: 917.595.2851

Market Value:
$122,386,272 a/o Dec 19, 2016

Shares Outstanding:
848,904,665 a/o Aug 29, 2016

Authorized Shares:
1,490,000,000 a/o Aug 26, 2014

817,204,665 a/o Aug 29, 2016

For more updated information please visit:

Transfer Agent:
Signature  Stock Transfer Inc. Plano TX  Ph # 972-612-4120

Investor Relations

Stonegate Capital Inc.
8201 Preston Road
Suite 325
Dallas, TX 75225
United States


   All News Releases:


What is Cell-in-a-Box®?

The Cell-in-a-Box® technology, developed by Austrianova, is a means to protect, isolate, storeand transport living cells. The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients. 
In biotechnology, the Cell-in-a-Box® technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost. 
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool. 
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box® technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans. 

Management Team:

Kenneth L. Waggoner, Chief Executive Officer and President

Gerald W. Crabtree, Ph.D. – Chief Operating Officer and Director

Carlos A. Trujillo – Chief Financial Officer and Director

Walter H. Gunzburg – Chief Scientific Officer

Dr. Matthias Lohr as Chairman of Scientific Advisory Board

Thomas Liquard - Chairman of the Audit Committe

  Dr. Eva Maria (Lilli) Brandtner – Director of Diabetes Program Development

Dr. Manuel Hidalgo, Scientific Advisory Board





-  The Board Monitor and The Board Assistants herewith, are not licensed brokers and assume NO responsibility for the actions, investment decisions, and or messages posted on this forum.
-  We do NOT recommend that anyone buy or sell any securities posted herewith. Any trade entered into risks the possibility of losing the funds invested.
-  There are no guarantees when buying or selling any security.



Cannabis Stocks News
Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PMCB News: Securities Registration Statement (simplified Form) (s-3) 09/13/2017 09:26:54 AM
PMCB News: Quarterly Report (10-q) 09/13/2017 06:06:08 AM
PMCB News: Current Report Filing (8-k) 09/06/2017 08:00:54 AM
PMCB News: Annual Report (10-k) 07/27/2017 05:24:39 PM
PMCB News: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 07/26/2017 09:00:00 AM
#75292  Sticky Note $PMCB PharmaCyte is preparing for a clinical trial $Pistol Pete$ 09/19/17 09:36:07 PM
#62231  Sticky Note in full/ #2/ 01-28-2017/ Keeping an Eye on mick 01/28/17 07:35:33 PM
#52881  Sticky Note Here is a very nice list of accomplishments... Peacefulwendy 09/28/16 11:17:44 AM
#75416   Pmcb isn’t the only one that is in frosr6 09/22/17 07:40:37 PM
#75415   Comparing real companies with a otc scam such frosr6 09/22/17 07:36:55 PM
#75414   Butterflies? I thought pmcb cell in a box frosr6 09/22/17 07:29:56 PM
#75413   A Dollar? I am sure anyone who knows concordia 09/22/17 07:01:07 PM
#75412   I'm loading up pureleaf 09/22/17 04:19:26 PM
#75411   Anyone see this at a dollar pps valuation Bud_Fox1 09/22/17 04:10:15 PM
#75410   Their are biotech's that will soon be producing concordia 09/22/17 04:00:58 PM
#75409   When will the news come ? In Q4 ziarfj 09/22/17 03:56:31 PM
#75408   Why would a large pharma company want anything Triple9 09/22/17 02:55:55 PM
#75405   I agree with you 100% ...Go Pmcb ferenc 09/22/17 12:50:43 PM
#75404   I am holding My "crap" as you say oldmusky 09/22/17 12:18:18 PM
#75403   Completely disagree, We have one shot at this, oldmusky 09/22/17 12:15:37 PM
#75402   So why not sell your 75,000 shares and cat3td7 09/22/17 12:12:25 PM
#75401   this is PMCBs and KWs MO.......look at their thenewmixer 09/22/17 12:11:28 PM
#75400   If you want a very sobering review of Triple9 09/22/17 10:59:52 AM
#75399   Well, I finally moved more money into my PINKribbon 09/22/17 10:51:00 AM
#75398   Yes companies fail because their treatments end up concordia 09/22/17 10:21:36 AM
#75397   what a crock- it still should not take NEWgene55 09/22/17 10:05:21 AM
#75396   One morning, hopefully soon, we are going to JODI1 09/22/17 10:02:56 AM
#75395   Because - they had to go back to NEWgene55 09/22/17 10:01:18 AM
#75394   I'm not the type to don tin foil Triple9 09/22/17 09:34:39 AM
#75393   Absolutely. KW has said repeatedly they get Triple9 09/22/17 09:28:12 AM
#75392   I have taken KW's silence in stride because oldmusky 09/22/17 09:17:07 AM
#75391   I am with you Rudy, holding holding holding. oldmusky 09/22/17 09:07:26 AM
#75390   thousands and thousands of shares later... seattlevulture 09/22/17 09:03:36 AM
#75389   Agree. The lack of updates is my biggest rcstock 09/22/17 09:00:22 AM
#75388   Although I do not like the profanity, I Tajim 09/22/17 08:52:18 AM
#75387   Exactly why I have amassed a PharmaCyte stock rudygerner 09/22/17 08:24:21 AM
#75386   Because they want to get it right 1234jklm 09/22/17 06:12:30 AM
#75385   Why take so long to submit IND Kochi1 09/22/17 12:53:53 AM
#75383   Austrianova is really Jensen in disguise! Shhh don’t frosr6 09/21/17 11:42:28 PM
#75381   That was the news. They partnered with Austrianova concordia 09/21/17 10:30:35 PM
#75380   Where is the GD NEWS?? Uboat 09/21/17 09:05:08 PM
#75378   $PMCB Dr. Matthias Löhr, Chairman of PharmaCyte's Medical $Pistol Pete$ 09/21/17 03:52:26 PM
#75376   Isn't placement in the body improved as well Mens et Manus 09/21/17 12:58:51 PM
#75375   In the Phase 1/2 clinical trial only a concordia 09/21/17 12:57:29 PM
#75374   Every time PMCB having an all out attack ferenc 09/21/17 12:39:42 PM
#75373   And this time they can keep giving doses 1234jklm 09/21/17 11:56:05 AM
#75372   ..First things first, let's keep in mind PharmaCyte's Triple9 09/21/17 11:31:20 AM
#75371   PharmaCyte Biotech on Schedule for 2016 Cancer Clinical concordia 09/21/17 11:31:02 AM
#75370   Remember when we were waiting in Austrianova to frosr6 09/21/17 11:27:03 AM
#75369   Our partners at Eurofins Lancaster Laboratories are developing Triple9 09/21/17 11:23:07 AM
#75368   They have done nothing with CIAB. Formula same frosr6 09/21/17 11:22:57 AM
#75367   What's that worth 100 bucks? "pmcb owns 14.5% frosr6 09/21/17 11:21:57 AM
#75365   What am I missing here, because this is Triple9 09/21/17 09:56:02 AM
#75364   ok its not hard you have said thenewmixer 09/21/17 09:32:31 AM
#75363   Austrianova is in Singapore and Thailand. I'm Triple9 09/21/17 09:31:31 AM
#75362   $PMCB The Chairman of Austrianova was one of $Pistol Pete$ 09/21/17 09:28:15 AM
#75361   There is a big difference between trading and concordia 09/21/17 09:25:57 AM
#75360   That's about the going rate for market research Triple9 09/21/17 09:24:44 AM